Recombinant Erythropoietin Market

Best Price Guarantee	Length	Publisher	Published Date	SKU
from $4,500	170 Pages	Coherent Market Insights	July, 2023	CMI18107603

Best Price Guarantee
Price	from $4,500
Length	170 Pages
Publisher	Coherent Market Insights
Published Date	July, 2023
SKU	CMI18107603

Recombinant Erythropoietin Market, By Type of Recombinant Erythropoietin (Epoetin Alfa, Darbepoetin Alfa), By Route of Administration (Subcutaneous, Intravenous), By Indication (Anemia Associated with Chronic Kidney Disease (CKD), Cancer-Related Anemia, HIV-Associated Anemia, Others), By End-user (Hospitals and Clinics, Dialysis Centers, Oncology Centers, Others), and By Geography (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa)- Size, Share, Outlook, and Opportunity Analysis, 2023 - 2030

Recombinant erythropoietin (rEPO) is a revolutionary medical development that has transformed the treatment of anemia and related conditions. Erythropoietin is a hormone naturally produced by the kidneys, stimulating the production of red blood cells (RBC) in the bone marrow. Recombinant DNA technology has made it possible to produce synthetic erythropoietin in the laboratory, resulting in the creation of rEPO. This breakthrough has provided has provided a highly effective and targeted approach to managing anemia, particularly in patients with chronic kidney diseases, cancer, and certain genetic disorders. By administrating rEPO, healthcare professionals can stimulate RBC production, improving oxygen carrying capacity and alleviating symptoms of anemia, such as fatigue and weakness. Furthermore, rEPO has demonstrated significant benefits in reducing the need for blood transfusion and enhancing quality of life for patients. The widespread adoption of recombinant erythropoietin has revolutionized anemia management and continues to play a crucial role in various medical fields.

Market Dynamics:

Rising prevalence of chronic kidney disease (ckd), increased incidence of cancer is anticipated to drive growth of the global recombinant erythropoietin market over the forecast period. Moreover, growing aging population, advancements in biotechnology is also expected to boost the growth of the global recombinant erythropoietin market over the forecast period. Emerging markets, untapped therapeutic areas, biosimilars, and collaborations and partnerships are expected to create growth opportunities for the global recombinant erythropoietin market during the forecast period.

However, stringent regulatory requirements, safety concerns and side effects, reimbursement challenges are expected to hamper growth of the recombinant erythropoietin market over the forecast period.

Key features of the study:

This report provides in-depth analysis of the global Recombinant Erythropoietin Market, and provides market size (US$ Billion) and compound annual growth rate (CAGR %) for the forecast period (2023–2030), considering 2022 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global Recombinant Erythropoietin Market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Amgen Inc., Johnson & Johnson (Janssen Pharmaceuticals), Pfizer Inc., Roche Holding AG, Novartis AG, Biocon Limited, Teva Pharmaceutical Industries Ltd., LG Chem Ltd., Sandoz International GmbH (a subsidiary of Novartis AG), Intas Pharmaceuticals Ltd., Dr. Reddy's Laboratories Ltd., Celltrion Inc., 3SBio Inc., CJ CheilJedang Corporation, BioSidus SA
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global Recombinant Erythropoietin Market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global Recombinant Erythropoietin Market

Detailed Segmentation:

Global Recombinant Erythropoietin Market, By Type of Recombinant Erythropoietin:
Epoetin Alfa
Darbepoetin Alfa
Global Recombinant Erythropoietin Market, By Route of Administration:
Subcutaneous
Intravenous
Global Recombinant Erythropoietin Market, By Indication:
Anemia Associated with Chronic Kidney Disease (CKD)
Cancer-Related Anemia
HIV-Associated Anemia
Others
Global Recombinant Erythropoietin Market, By End User:
Hospitals and Clinics
Dialysis Centers
Oncology Centers
Others
Global Recombinant Erythropoietin Market, By Region:
North America
Europe
Asia Pacific
Latin America
Middle East and Africa
Company Profiles:
Amgen Inc.
Johnson & Johnson (Janssen Pharmaceuticals)
Pfizer Inc.
Roche Holding AG
Novartis AG
Biocon Limited
Teva Pharmaceutical Industries Ltd.
LG Chem Ltd.
Sandoz International GmbH (a subsidiary of Novartis AG)
Intas Pharmaceuticals Ltd.
Dr. Reddy's Laboratories Ltd.
Celltrion Inc.
3SBio Inc.
CJ CheilJedang Corporation
BioSidus SA

1. Research Objectives and Assumptions: Research Objectives; Assumptions; Abbreviations
2. Market Purview: Report Description; Market Definition and Scope; Executive Summary; Market Snapshot, By Type of Recombinant Erythropoietin; Market Snapshot, By Route of Administration; Market Snapshot, By Indication; Market Snapshot, By End User; Market Snapshot, By Region; Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis: Market Dynamics; Drivers; Rising prevalence of chronic kidney disease (ckd); Increased incidence of cancer; Growing aging population; Restraints; Growing Focus on Biosimilars; Shift towards Long-Acting Formulations; Focus on Patient-Centric Delivery Systems; Opportunities; Emerging Markets; Untapped Therapeutic Areas; Biosimilars; Impact Analysis; Key Highlights; Regulatory Scenario; Product launch/Approvals; PEST Analysis; PORTER’s Analysis; Merger and Acquisition Scenario
4. Global Recombinant Erythropoietin Market – Impact of Coronavirus (COVID-19) Pandemic: COVID-19 Epidemiology; Supply Side and Demand Side Analysis; Economic Impact
5. Global Recombinant Erythropoietin Market , By Type of Recombinant Erythropoietin, 2023-2030, (US$ Bn): Introduction; Market Share Analysis, 2023 and 2030 (%); Y-o-Y Growth Analysis, 2018 – 2030; Segment Trends; Epoetin Alfa; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2023-2030,(US$ Bn); Darbepoetin; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2023-2030,(US$ Bn)
6. Global Recombinant Erythropoietin Market , By Route of Administration, 2023-2030, (US$ Bn): Introduction; Market Share Analysis, 2023 and 2030 (%); Y-o-Y Growth Analysis, 2018 – 2030; Segment Trends; Subcutaneous; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2023-2030,(US$ Billion); Intravenous; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2023-2030,(US$ Billion)
7. Global Recombinant Erythropoietin Market, By Indication, 2023-2030, (US$ Bn): Introduction; Market Share Analysis, 2023 and 2030 (%); Y-o-Y Growth Analysis, 2018 – 2030; Segment Trends; Anemia Associated with Chronic Kidney Disease (CKD); Introduction; Market Size and Forecast, and Y-o-Y Growth, 2023-2030,(US$ Billion); Cancer-Related Anemia; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2023-2030,(US$ Billion); HIV-Associated Anemia; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2023-2030,(US$ Billion); Others; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2023-2030,(US$ Billion)
8. Global Recombinant Erythropoietin Market , By End User, 2023-2030, (US$ Bn): Introduction; Market Share Analysis, 2023 and 2030 (%); Y-o-Y Growth Analysis, 2018 – 2030; Segment Trends; Hospitals and Clinics; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2023-2030,(US$ Billion); Dialysis Centers; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2023-2030,(US$ Billion); Oncology Centers; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2023-2030,(US$ Billion); Others; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2023-2030,(US$ Billion)
9. Global Recombinant Erythropoietin Market , By Region, 2023-2030, (US$ Bn): Introduction; Market Share Analysis, By Country, 2023 and 2030 (%); Y-o-Y Growth Analysis, For Country 2018 –2030; Country Trends; North America; Introduction; Market Size and Forecast, and Y-o-Y Growth, By Type of Recombinant Erythropoietin , 2023-2030,(US$ Bn); Market Size and Forecast, and Y-o-Y Growth, By Route of Administration , 2023-2030,(US$ Bn); Market Size and Forecast, and Y-o-Y Growth, By Indication , 2023-2030,(US$ Bn); Market Size and Forecast, and Y-o-Y Growth, By End User , 2023-2030,(US$ Bn); Europe; Introduction; Market Size and Forecast, and Y-o-Y Growth, By Type of Recombinant Erythropoietin , 2023-2030,(US$ Bn); Market Size and Forecast, and Y-o-Y Growth, By Route of Administration , 2023-2030,(US$ Bn); Market Size and Forecast, and Y-o-Y Growth, By Indication , 2023-2030,(US$ Bn); Market Size and Forecast, and Y-o-Y Growth, By End User , 2023-2030,(US$ Bn); Asia Pacific; Introduction; Market Size and Forecast, and Y-o-Y Growth, By Type of Recombinant Erythropoietin , 2023-2030,(US$ Bn); Market Size and Forecast, and Y-o-Y Growth, By Route of Administration , 2023-2030,(US$ Bn); Market Size and Forecast, and Y-o-Y Growth, By Indication , 2023-2030,(US$ Bn); Market Size and Forecast, and Y-o-Y Growth, By End User , 2023-2030,(US$ Bn); Latin America; Introduction; Market Size and Forecast, and Y-o-Y Growth, By Type of Recombinant Erythropoietin , 2023-2030,(US$ Bn); Market Size and Forecast, and Y-o-Y Growth, By Route of Administration , 2023-2030,(US$ Bn); Market Size and Forecast, and Y-o-Y Growth, By Indication , 2023-2030,(US$ Bn); Market Size and Forecast, and Y-o-Y Growth, By End User , 2023-2030,(US$ Bn); Middle East & Africa; Introduction; Market Size and Forecast, and Y-o-Y Growth, By Type of Recombinant Erythropoietin , 2023-2030,(US$ Bn); Market Size and Forecast, and Y-o-Y Growth, By Route of Administration , 2023-2030,(US$ Bn); Market Size and Forecast, and Y-o-Y Growth, By Indication , 2023-2030,(US$ Bn); Market Size and Forecast, and Y-o-Y Growth, By End User , 2023-2030,(US$ Bn)
10. Competitive Landscape: Amgen Inc.; Company Highlights; Product Portfolio; Key Developments; Financial Performance; Strategies; Johnson & Johnson (Janssen Pharmaceuticals); Pfizer Inc.; Roche Holding AG; Novartis AG; Biocon Limited; Teva Pharmaceutical Industries Ltd.; LG Chem Ltd.; Sandoz International GmbH (a subsidiary of Novartis AG); Intas Pharmaceuticals Ltd.; Dr. Reddy's Laboratories Ltd.; Celltrion Inc.; 3SBio Inc.; CJ CheilJedang Corporation; BioSidus SA; Analyst Views
11. Section: Research Methodology; About us; *Browse 24 market data tables and 28 figures on "Global Recombinant Erythropoietin Market” - Global forecast to 2030